Biotech's Helix Award Honors Top Performers Onyx Pharmaceuticals and Actelion
26 February 2004 - 5:29AM
PR Newswire (US)
Biotech's Helix Award Honors Top Performers Onyx Pharmaceuticals
and Actelion NEW YORK, Feb. 25 /PRNewswire/ -- Onyx Pharmaceuticals
Inc. and Actelion Ltd. have won the 2004 James D. Watson Helix
Awards. The winners, selected by peer vote on the basis of their
2003 performance, are being honored today at a BIO CEO &
Investor Conference plenary luncheon. "These companies exemplify
the ideals of the Helix Award, the biotechnology industry's highest
company honor," said BIO President Carl B. Feldbaum. "In 2003, both
advanced new therapies for unmet medical needs and delivered
outstanding returns to investors." During 2003, the winner in the
mid-cap company category, Onyx Pharmaceuticals (NASDAQ:ONXX),
focused its resources to rapidly advance the clinical development
of its lead compound, an oral cancer product now in Phase III
testing for kidney cancer. "We are humbled and honored to have been
selected by our industry peers for this prestigious award," said
Hollings C. Renton, Onyx's president and CEO. "Together with our
collaborator, Bayer, we made important scientific and clinical
progress with our lead anti-cancer compound, BAY 43-9006,
culminating in the initiation of the first pivotal Phase III
trial." Actelion Ltd. (SWX:ATLN), the international winner, is a
biopharmaceutical company headquartered in Allschwil, Switzerland.
Actelion markets two products: Tracleer, an orally available
endothelin receptor antagonist for pulmonary arterial hypertension,
and Zavesca, an oral Gaucher's disease drug. "Actelion is very
proud to be recognized and honored by its peers in the United
States for our work in helping to improve the health and lives of
people everywhere," said CEO Jean-Paul Clozel, M.D. "2003 was a
significant year for us as we achieved critical milestones by not
only successfully supporting our products Tracleer and Zavesca in
the market place, but also by achieving important milestones in
research and clinical trials." Genentech, of South San Francisco,
received the Helix Award in the large- cap category Feb. 24. The
James D. Watson Helix Award honors leadership in three distinct
areas: scientific innovation, company growth and corporate
citizenship. It is presented by the Long Island Life Sciences
Initiative (LILSI) and is jointly sponsored by BIO, Stony Brook
University and The Center for Biotechnology. The competition is
open to public and private, U.S. or foreign-based biotechnology
companies. An independent panel of judges reviewed this year's
submissions. LILSI is a not-for-profit trade association created to
address issues of strategic importance to the biotechnology,
pharmaceutical, medical device and life science technology-based
industries. LILSI advocates on behalf of public policy that will
improve the Long Island region's business climate for life science
companies and enhance the research and business infrastructure that
is vital to their success. More information on LILSI can be found
at http://www.lilsi.org/. BIO represents more than 1,000
biotechnology companies, academic institutions, state biotechnology
centers and related organizations in all 50 U.S. states and 33
other nations. BIO members are involved in the research and
development of health-care, agricultural, industrial and
environmental biotechnology products. For more information, please
visit http://www.bio.org/. DATASOURCE: Biotechnology Industry
Organization CONTACT: Debbie Strickland of BIO, +1-202-962-9200 Web
site: http://www.bio.org/ http://www.lilsi.org/
Copyright
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More Onyx Pharmaceuticals, (MM) News Articles